Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Al | INSM Message Board Posts

Insmed Incorporated

  INSM website

INSM   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  46232 of 46390  at  6/12/2019 8:27:26 PM  by

bohemian


 In response to msg 46231 by  insmhistorian
view thread

Re: Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)

The company’s chief executive, Rob Neville, believes that data from the Impala trial in autoimmune pulmonary alveolar proteinosis (aPAP), due in June, could spur interest in the company. Indeed, he tells Vantage that Savara hopes to follow in the footsteps of another lung disease player, Insmed, which is making a good fist of marketing Arikayce alone, and is now worth a cool $2.5bn.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 175
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2018 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...